Si desitges distingir els teus productes, serveis o tots dos dels d'una altra empresa, és possible que necessitis una marca o nom comercial. Descobreix què són, en què consisteix el seu procediment de registri i què implica.
Información sobre los plazos de presentación de solicitudes de transformación de marcas de la Unión Europea en marca nacional española. Más información
Si tens un nou dispositiu, producte o procediment que resolgui un problema tècnic o tingui un avantatge pràctic, existeixen diferents formis de protegir-ho a Espanya i en altres països. Descobreix com fer-ho.
La teva innovació resideix en l'estètica, l'ornamentació o l'aparença del teu producte? Protegeix-la mitjançant un disseny industrial. Descobreix quins drets confereix el registri i com realitzar la tramitació.
Els patents publicades a tot el món són una valuosa font d'informació científica, tècnica i comercial.
reembolso del 75% del coste de Búsquedas e Informes Tecnológicos de Patentes. Más información*
Si ets emprenedor/a o una empresa i vols potenciar i millorar la rendibilitat del teu negoci protegint de forma adequada els actius intangibles de la teva organització, en aquest espai trobaràs el necessari.
115
resultados
Última actualización
19/10/2024 [06:51:00]
Resultados 50 a 75 de 115
Resumen de: US2024335360A1
The present invention relates to stabilizing an oil in water nanoemulsion in a pressurized container. The nanovesicles comprised in the nanoemulsion are particularly stable in regard to vesicle size and vesicle size homogeneity after long-term storage at different temperatures.
Resumen de: WO2024211857A1
This disclosure features novel lipid nanoparticle formulations and uses thereof. The lipid nanoparticle ("LNP") includes an encapsulated therapeutic agent and an aqueous solution comprising a salt and an anionic polymer, wherein the salt and the anionic polymer are dissolved in the aqueous solution, thereby forming polymer coated lipid nanoparticle ("PCLNP"). Lipid nanoparticles of this disclosure are useful in the process of lyophilization or freeze drying and decrease nanoparticle aggregation and maintain efficacy once reconstituted.
Resumen de: WO2024210160A1
The invention provides a complex for delivering an active substance, comprising a delivery vehicle for the active substance and a ligand specific to a target cell, the ligand being added to the outer surface of the delivery vehicle, wherein the delivery vehicle is comprised of an anchor molecule, a first binding partner is covalently bonded to the ligand at a ratio of 1-4 molecules of the first binding partner per one molecule of the ligand; a second binding partner is covalently bonded to the anchor molecule whereby the second binding partner is immobilized to the delivery vehicle; and the first binding partner is covalently bonded to the second binding partner.
Resumen de: WO2024209064A1
The present invention relates to oil in water nanoemulsions which are essentially free of propylene glycol. The nanovesicle formulations are particularly stable in regard to shelf life at different storage temperatures.
Resumen de: WO2024209065A1
The present invention relates to stabilizing an oil in water nanoemulsion in a pressurized container. The nanovesicles comprised in the nanoemulsion are particularly stable in regard to vesicle size and vesicle size homogeneity after long-term storage at different temperatures.
Resumen de: WO2024209013A1
The present invention relates to the field of lipid nanoparticles (LNPs). In particular, the present invention relates to an LNP composition comprising a cationic or cationically ionisable lipid or lipid-like material, a helper lipid, a lipopolymer, and a monomycoloyl glycerol (MMG) analogue. The LNP composition is particularly useful as a vaccine composition.
Resumen de: WO2024209011A1
The present invention has been made within the field of nanoparticles and relates to a nanoparticle composition comprising the polymer poly(D,L-lactic-co-glycolic acid) (PLGA). In particular the present invention relates to a lipid polymer hybrid nanoparticle composition comprising a cationic or cationically ionisable lipid or lipid-like material, a helper lipid, a lipopolymer, and one or more variants of PLGA. The nanoparticle composition is particularly useful for delivery of nucleic acid molecules, specifically mRNA; thereby making them highly suitable for use in vaccines, such as for the prevention and/or treatment of infectious diseases.
Resumen de: US2024335380A1
The present invention relates to oil in water nanoemulsions which are essentially free of propylene glycol. The nanovesicle formulations are particularly stable in regard to shelf life at different storage temperatures.
Resumen de: WO2024211576A1
Provided herein are compositions containing a poloxamer copolymer, and a plurality of viral nanoparticles, such as Cowpea mosaic virus (CPMV), as an anticancer agent that maintains the integrity of the CPMV.
Resumen de: WO2024211645A1
Mucosal patches are disclosed that have a support layer supporting an active layer that has a collagen carbon dot nanocomposite carrying an active agent. The collagen carbon dot nanocomposite is absorbable through a mucosa. The mucosal patches are part of various methods of treatment.
Resumen de: WO2024211881A1
A pharmaceutical composition includes a therapeutically effective amount of Rimegepant or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier, wherein the pharmaceutical composition is in a form of a liquid suspension or a reconstitutable powder composition, and wherein the Rimegepant or the pharmaceutically acceptable salt thereof is provided in a micronized or nano milled form.
Resumen de: WO2024210692A1
Hydrophobic ceramides are of limited use due to having extremely low solubility in aqueous solutions, and have low cell transduction efficiency when used as a drug. The present invention provides a highly water-dispersible composition having a high ceramide content. A high dose of a hydrophobic ceramide can be easily delivered to a target in the body through the present invention to increase the utility as a highly water-dispersible drug carrier or pharmaceutical composition according to the intended purpose.
Resumen de: WO2024209481A1
The present invention describes the synthesis of a novel self-assembled organic nanosensor. The self- assembled organic nanosensor is naphthalene sulphonate backbone with a size distribution of 40 - 2000 nanometers. The self-assembled organic nanosensor exhibits very low auto-fluorescence however, it exhibits high fluorescence activity in presence of albumin protein therefore, the signal is to noise ratio will be high. The fluorescence generated is directly proportional to the concentration of the albumin protein and can be used for quantification of the albumin in sample. The self-assembled organic nanosensor can quantify 0.1 mg/L -3500 mg/L range of albumin concentration linearly. The nanosensor exhibits fluorescence between 5 to 10 seconds of introduction of self-assembled organic nanosensor to the sample containing albumin. The interaction with self-assembled organic nanosensor exhibits the stability to the albumin protein for 20 days in aqueous solution and is stable between - 80 degree to + 95 degree Celsius.
Resumen de: WO2024209404A1
The present disclosure relates to an RNA delivery vehicle comprising lipid nanoparticles comprising the RNA therein, and a RNA-binding protein or peptide coated on the exterior surface of the lipid nanoparticle, and uses thereof.
Resumen de: US2024335559A1
The present invention relates to a lipidoid of general formula I, wherein X is selected from —C(═O)NH—, —C(═O)O—, —C(═S)O—, —C(═O)S—, —C(═S)S—, —C(═O)NHNH—, —CH2—, —O—, —OC(═O)—, —S—, —SC(═O)—, —NH—, —NHNH—, —NHC(═O)—, —NHNHC(═O)—, —C═C—, —CH═CH—, a five-membered heterocycle containing at least 2 nitrogen atoms, —CH2C(═O)NH—, —CH2C(═S)O—, —CH2C(═S)S—, —CH2C(═O)NHNH—, —N═CH—, —CH═N—, —NH—N═CH—, and —CH═N—NH—; Y is alkylene C2-C10 chain; R1 is selected from alkyl C1-C46, alkenyl C2-C46, alkynyl C2-C46; Z is selected from H, —OH, —CH3, —CH2OH, —NH2, —C(═O)NH2, —CONH(CH2)2OH, —CON(CH2)2OH2, —CONHCH(CH2OH)2, —CONHCH2CH(—OH)CH2OH, —CONH(CH2)2C(═O)NH2, —CONCH2C(═O)NH22, —CONH(CH2)2NHC(═O)NH2, —CONH(CH2)3—N+(CH3)2—(CH2)2—SO3—, —CONH(CH2)3—N+(CH3)2—(CH2)2—COO−, —COO(CH2)2—O—P(═O)(O—)—O(CH2)2—N+(CH3)3, —N+(CH3)2—(CH2)3—SO3—, —N+(CH3)2—(CH2)2—COO−, formula (II), and formula (III), wherein R2 is independently selected from hydrogen and —CH3; E is independently selected from O and S atoms; n is an integer within the range of from 1 to 5; and T is selected from —X—Y—N(R1)2, —C(═O)O(C1-C3 alkyl), —C(═O)OCH2CH2OH, formula (IV), formula (V), formula (VI), —C(═O)OH, —CONH(CH2)2OH, —CON(CH2)2OH2, —CONHCH(CH2OH)2, CONH(CH2)2C(═O)NH2, —CONCH2C
Resumen de: US2024335550A1
Mucosal patches are disclosed that have a support layer supporting an active layer that has a collagen carbon dot nanocomposite carrying an active agent. The collagen carbon dot nanocomposite is absorbable through a mucosa. The mucosal patches are part of various methods of treatment.
Resumen de: US2024335541A1
The present disclosure describes compositions, preparations, nanoparticles (such as lipid nanoparticles), and/or nanomaterials and methods of their use.
Resumen de: US2024335543A1
The present disclosure describes compositions, preparations, nanoparticles (such as lipid nanoparticles), and/or nanomaterials and methods of their use.
Resumen de: US2024335542A1
The present disclosure describes compositions, preparations, nanoparticles (such as lipid nanoparticles), and/or nanomaterials and methods of their use.
Resumen de: US2024335540A1
In one aspect, compositions are described herein. A composition described herein comprises a nanoparticle, a therapeutic species, and a linker joining the nanoparticle to the therapeutic species. The linker joining the nanoparticle to the therapeutic species comprises a Diels-Alder cyclo-addition reaction product. Additionally, in some embodiments, the nanoparticle is a core-shell-shell metal nanoparticle.
Resumen de: US2024335532A1
The present disclosure relates to nanoparticulate vaccine adjuvants, and to vaccine compositions which contain nanoparticulate vaccine adjuvants; to methods of preparing such adjuvants and compositions; and to methods of using such compositions and adjuvants for vaccination. The vaccine adjuvants disclosed herein are effective for enhancing the immune response to vaccination.
Resumen de: WO2024207827A1
A periodontal microneedle loaded with near-infrared responsive composite bilirubin nanoparticles and a preparation method therefor. The bilirubin-gelatin complex nanoparticles in the nanoparticles are sequentially coated with a macrophage cell membrane and an organic-metal coordination supramolecular network coating layer on the surface, and modified with phospholipid-polyethylene glycol-folic acid on the outer surface, wherein the organic ligand of the organic-metal coordination supramolecular network coating is anthocyanin, and the coordinated metal ion is ferric ion. The nanoparticles can be used for remodel immune homeostasis in periodontitis by means of the dual functions of stimulating the apoptosis of M1 macrophages by means of a photothermal effect and inducing M2 polarization of M1 macrophages by means of ROS scavenging.
Resumen de: WO2024207721A1
Disclosed in the present invention are a multi-tail type ionizable lipid, a preparation method therefor and the use thereof. The structural formula of the multi-tail type ionizable lipid of the present invention is as follows, wherein R1 and R2 are the same or different, and each is hydrogen or an alkyl chain or an alkyl ring consisting of 1 to 6 carbons, or R1 and R2 together form a nitrogen-containing alkyl ring; L1 and L2 are the same or different, and each is an alkyl chain or an unsaturated hydrocarbyl group consisting of 1 to 6 carbons in length; and R is an alkyl group, an alkyl ring, an unsaturated hydrocarbyl group, or a heterohydrocarbyl group; and n = 1 to 6, m1 = 1 to 15, m2 = 1 to 15, and x = 0 to 5. The synthesis method for preparing the multi-tail type ionizable lipid provided in the present invention is simple, the raw materials are common and easy to obtain, and the route design is rational. A large amount of an ionizable lipid can be prepared by means of a few steps of addition reaction, facilitating high-throughput screening of materials; and the obtained ionizable lipid can effectively express RNA in vivo and in vitro, and has the advantages of high efficiency, low toxicity, etc.
Resumen de: WO2024207635A1
Provided in the present invention are an ASP-ELP for reducing immunogenicity and enhancing an anti-tumor effect, and a preparation method therefor and the use thereof. According to the present invention, for the first time, the artificial intelligence tool AlphaFold2 is used to fuse ELPs of different lengths and compositions with ASP. The designed ASP-ELPs have multiple advantages compared with bulk drug asparaginase ASP and long-acting asparaginase PEG-ASP. In vivo and in vitro experimental results show that the ASP-ELPs are superior to the long-acting asparaginase in the aspects of enzyme activity retention rate, storage stability, pharmacokinetics, immunogenicity, biosafety, anti-cancer efficacy, etc. The present invention not only provides a new design method for pharmaceutical research and development of a protein-macromolecular polymer on the basis of artificial intelligence-assisted design, but also shows that the ASP-ELPs are a new efficient therapy for treating hematological malignancies.
Nº publicación: AU2023262576A1 10/10/2024
Solicitante:
STRAND THERAPEUTICS INC
STRAND THERAPEUTICS INC
Resumen de: AU2023262576A1
The present disclosure relates to lipid nanoparticles (LNPs) comprising VEE replicon, wherein the LNPs are useful for selectively reducing and/or avoiding the expression of a payload within the liver. The present disclosure also relates to the use of such LNPs to treat various diseases and disorders.
BOPI
Sede Electrónica
